[Form 4] Akero Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Scott A. Gangloff, Chief Technology Officer of Akero Therapeutics (AKRO), reported a securities transaction dated 08/15/2025. The filing shows an acquisition of 2,600 shares/options with a reported price of $19.62, increasing the reporting person’s beneficial ownership to 26,351 shares following the transaction.

The filing also discloses a derivative position: a stock option with a $19.62 exercise price covering 20,384 underlying common shares, of which 17,784 derivative securities are reported as beneficially owned. The option vests 25% on April 29, 2025, with the balance vesting in 36 equal monthly installments, subject to continued service. The form is signed by an attorney-in-fact on 08/19/2025.

Positive

• Reporting person acquired 2,600 securities at $19.62 on 08/15/2025
• Beneficial ownership increased to 26,351 shares following the transaction
• Vesting schedule disclosed: 25% vested April 29, 2025, remainder in 36 monthly installments
• Detailed derivative position provided: option covering 20,384 underlying common shares with exercise price $19.62

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider acquisition increases CTO's equity stake; transaction appears standard for executive compensation.

The Form 4 reports a transaction dated 08/15/2025 in which Scott A. Gangloff acquired 2,600 shares/options at a reported price of $19.62, bringing his total beneficial ownership to 26,351 shares. A related derivative position shows a stock option with a $19.62 exercise price covering 20,384 underlying shares and 17,784 derivative securities reported as owned. Vesting terms specify 25% vested on April 29, 2025, with remaining vesting over 36 monthly installments, conditioned on continued service. From a trading-disclosure perspective, this is a straightforward reporting of executive equity compensation and resulting ownership levels.

Corporate Governance Expert

TL;DR: Disclosure aligns with standard Section 16 reporting; vesting schedule and ownership change are clearly documented.

The Form 4 provides required disclosure of changes in beneficial ownership for an executive officer. It specifies the transaction code (M), the number of securities acquired (2,600), the exercise/conversion price ($19.62), and post-transaction ownership (26,351 shares). The filing includes the vesting schedule for the option and is executed via attorney-in-fact. The document fulfills routine governance and disclosure obligations without additional qualifiers or caveats in the filing itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gangloff Scott A.

(Last) (First) (Middle)

C/O AKERO THERAPEUTICS, INC.

601 GATEWAY BOULEVARD, SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		M		2,600	A	$19.62	26,351	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (Right to Buy)	$19.62	08/15/2025		M			2,600	(1)	04/28/2034	Common Stock	20,384	$0	17,784	D

Explanation of Responses:

1. Twenty-five (25) percent of the shares subject to this option shall vest and become exercisable on April 29, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Jonathan Young, Attorney-in-Fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Scott A. Gangloff report on Form 4 for AKRO?

The Form 4 reports an acquisition of 2,600 securities on 08/15/2025 at a reported price of $19.62.

How many shares does the reporting person beneficially own after the transaction (AKRO)?

The filing shows 26,351 shares beneficially owned following the reported transaction.

What derivative securities are disclosed by the reporting person in the AKRO Form 4?

A stock option with a $19.62 exercise price covering 20,384 underlying common shares is disclosed, with 17,784 derivative securities reported as owned.

What are the vesting terms for the option reported in the AKRO filing?

The option vests 25% on April 29, 2025, with the remainder vesting in 36 equal monthly installments, subject to continued service.

Who signed the Form 4 for Scott A. Gangloff and when?

The form was signed by Jonathan Young, Attorney-in-Fact on 08/19/2025.